Satter Muneer A 13D and 13G filings for Akebia Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 5:00 pm Sale |
2024-12-31 | 13G | Akebia Therapeutics, Inc. AKBA |
Satter Muneer A | 5,747,906 2.600% |
-10,457,213 (-64.53%) |
Filing |
| 2024-02-09 4:00 pm Purchase |
2023-12-31 | 13G | Akebia Therapeutics, Inc. AKBA |
Satter Muneer A | 16,205,119 8.600% |
1,115,000 (+7.39%) |
Filing |
| 2023-02-10 1:08 pm Purchase |
2022-12-31 | 13G | Akebia Therapeutics, Inc. AKBA |
Satter Muneer A | 15,090,119 8.200% |
1,225,789 (+8.84%) |
Filing |
| 2022-12-19 4:10 pm Purchase |
2022-12-08 | 13G | Akebia Therapeutics, Inc. AKBA |
Satter Muneer A | 13,864,330 7.500% |
10,797,287 (+352.04%) |
Filing |